Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
The United Laboratories International Holdings Limited (3933.HK)
HKD9.23
+0.11 (+1.21%)
HK HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address
6 Fuk Wang Street
Yuen Long, HK
Yuen Long, HK
CEO
Hoi Shan Tsoi
Website
tul.com.cn
IPO
2007-06-15
ISIN KYG8813K1085
Also trades on
Hong Kong Stock Exchange · 3933.HK (HKD)
Other OTC · ULIHF (USD)
Description
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD9.23
+0.11 (+1.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
0.31
Float Shares
1.12B
Free Float %
56.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.65% | -3.93% | -6.18% | -32.31% | -31.09% | -24.07% | -39.81% | +25.53% | +21.38% | +176.73% | +165.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
9.23
DCF (Unlevered)
20.42
+121.2%
DCF (Levered)
57.99
+528.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
78% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 7 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.87
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-4.0% Q4'25: -16.7% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-24.0% Q4'25: -87.4% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+23.2% ★ Q4'25: +10.9% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.8% ★ Q4'25: -0.5% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+16.3% ★ Q4'25: -1.0% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.8% Q4'25: +7.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.76× ★ Q4'25: 4.43× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 5 EPS Ana. |
Dec 2027 9 Rev. Ana. 5 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.18B
est: 5.51B (-5.8%)
|
5.65B
est: 5.83B (-3.0%)
|
5.97B
est: 6.13B (-2.7%)
|
6.42B
est: 6.24B (+2.9%)
|
6.45B
est: 7.96B (-19.0%)
|
6.08B
est: 7.10B (-14.4%)
|
6.83B
est: 7.83B (-12.8%)
|
7.51B
est: 8.91B (-15.7%)
|
8.39B
est: 9.11B (-7.9%)
|
8.77B
est: 11.18B (-21.6%)
|
9.70B
est: 11.81B (-17.9%)
|
11.33B
est: 12.17B (-6.9%)
|
13.74B
est: 13.03B (+5.4%)
|
13.76B
est: 14.45B (-4.8%)
|
13.21B
est: 13.21B (0.0%)
|
13.27B
12.49B – 13.95B
+0.4% YoY
|
14.25B
13.49B – 15.08B
+7.4% YoY
|
15.13B
14.29B – 15.96B
+6.2% YoY
|
17.78B
16.79B – 18.76B
+17.5% YoY
|
19.58B
18.49B – 20.66B
+10.1% YoY
|
| EBITDA |
641.38M
est: 1.35B (-52.3%)
|
762.42M
est: 414.38M (+84.0%)
|
857.38M
est: 499.14M (+71.8%)
|
1.40B
est: 1.02B (+36.6%)
|
1.18B
est: 989.41M (+19.0%)
|
1.04B
est: 631.82M (+65.1%)
|
1.36B
est: 319.24M (+324.8%)
|
1.63B
est: 727.53M (+124.7%)
|
1.69B
est: 1.32B (+28.1%)
|
1.83B
est: 1.44B (+26.7%)
|
1.98B
est: 1.57B (+26.2%)
|
2.54B
est: 1.71B (+48.0%)
|
3.98B
est: 3.06B (+29.8%)
|
3.35B
est: 3.44B (-2.5%)
|
2.83B
est: 3.11B (-8.7%)
|
3.12B
2.93B – 3.28B
+0.4% YoY
|
3.35B
3.17B – 3.54B
+7.4% YoY
|
3.56B
3.36B – 3.75B
+6.2% YoY
|
4.18B
3.95B – 4.41B
+17.5% YoY
|
4.60B
4.35B – 4.86B
+10.1% YoY
|
| EBIT |
273.50M
est: 1.14B (-75.9%)
|
373.00M
est: 289.96M (+28.6%)
|
412.34M
est: 405.86M (+1.6%)
|
828.03M
est: 888.63M (-6.8%)
|
489.81M
est: 1.01B (-51.5%)
|
332.72M
est: 528.15M (-37.0%)
|
578.61M
est: 91.51M (+532.3%)
|
903.03M
est: 416.49M (+116.8%)
|
1.02B
est: 1.07B (-4.7%)
|
1.23B
est: 1.31B (-6.0%)
|
1.38B
est: 1.42B (-2.9%)
|
2.02B
est: 1.56B (+29.4%)
|
3.41B
est: 2.69B (+26.8%)
|
2.81B
est: 3.02B (-6.8%)
|
2.22B
est: 2.73B (-18.5%)
|
2.74B
2.58B – 2.88B
+0.4% YoY
|
2.94B
2.78B – 3.11B
+7.4% YoY
|
3.12B
2.95B – 3.29B
+6.2% YoY
|
3.67B
3.46B – 3.87B
+17.5% YoY
|
4.04B
3.82B – 4.26B
+10.1% YoY
|
| Net Income |
84.39M
est: 881.08M (-90.4%)
|
130.42M
est: 89.49M (+45.7%)
|
37.54M
est: 141.86M (-73.5%)
|
544.62M
est: 38.75M (+1,305.6%)
|
92.41M
est: 663.98M (-86.1%)
|
-272.36M
est: 99.64M (-373.3%)
|
81.76M
est: -256.89M (+131.8%)
|
682.93M
est: 101.44M (+573.3%)
|
641.76M
est: 701.07M (-8.5%)
|
702.99M
est: 748.35M (-6.1%)
|
988.10M
est: 813.28M (+21.5%)
|
1.58B
est: 2.24B (-29.3%)
|
2.70B
est: 2.71B (-0.1%)
|
2.66B
est: 3.05B (-12.8%)
|
2.09B
est: 2.33B (-10.3%)
|
1.22B
801.76M – 1.72B
-47.4% YoY
|
1.49B
1.07B – 2.13B
+22.1% YoY
|
1.71B
1.26B – 2.89B
+14.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
1.20B
est: 1.17B (+2.6%)
|
1.35B
est: 1.27B (+5.7%)
|
1.40B
est: 1.46B (-4.6%)
|
1.58B
est: 1.44B (+9.6%)
|
1.70B
est: 1.92B (-11.6%)
|
1.67B
est: 1.83B (-8.5%)
|
1.67B
est: 1.58B (+6.2%)
|
1.84B
est: 2.07B (-11.3%)
|
2.22B
est: 1.88B (+17.8%)
|
2.22B
est: 2.60B (-14.4%)
|
2.33B
est: 2.82B (-17.2%)
|
2.37B
est: 3.09B (-23.4%)
|
2.38B
est: 2.51B (-5.1%)
|
2.30B
est: 2.82B (-18.6%)
|
2.30B
est: 2.55B (-9.6%)
|
2.56B
2.41B – 2.69B
+0.4% YoY
|
2.75B
2.60B – 2.91B
+7.4% YoY
|
2.92B
2.75B – 3.08B
+6.2% YoY
|
3.43B
3.24B – 3.62B
+17.5% YoY
|
3.78B
3.56B – 3.98B
+10.1% YoY
|
| EPS |
0.06
est: 0.26 (-76.8%)
|
0.09
est: 0.09 (-8.7%)
|
0.02
est: 0.05 (-54.0%)
|
0.33
est: 0.35 (-6.1%)
|
0.06
est: 0.27 (-79.1%)
|
-0.17
est: 0.02 (-1,031.8%)
|
0.05
est: 0.25 (-79.6%)
|
0.37
est: 0.45 (-18.0%)
|
0.39
est: 0.38 (+2.2%)
|
0.40
est: 0.52 (-23.6%)
|
0.54
est: 0.73 (-26.5%)
|
0.87
est: 0.69 (+25.6%)
|
1.49
est: 1.49 (+0.1%)
|
1.46
est: 1.62 (-9.8%)
|
1.11
est: 1.23 (-10.0%)
|
0.67
0.43 – 0.91
-45.8% YoY
|
0.85
0.57 – 1.13
+27.2% YoY
|
0.98
0.67 – 1.53
+15.2% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.32B
OE per share TTM
1.83
Owner's Yield
19.34%
Maintenance CapEx ratio
997.78%
Maint CapEx / Avg PPE
67.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 82 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Roundhill Investments - GLP-1 & Weight Loss ETF OZEM | 2.78% | 1.77M | 0.59% |
| 2 | Vident International Equity Strategy ETF VIDI | 0.35% | 1.39M | 0.61% |
| 3 | Fidelity Emerging Markets Quality Income UCITS ETF INC-USD FEME.L | 0.26% | 543.2K | 0.50% |
| 4 | Fidelity Emerging Markets Limited FEMI.L | 0.26% | 543.2K | 0.50% |
| 5 | First Trust Developed Markets ex-US Small Cap AlphaDEX Fund FDTS | 0.23% | 30.3K | 0.80% |
| 6 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.15% | 1.69M | 0.40% |
| 7 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.11% | 80.3K | 0.74% |
| 8 | iShares International Small-Cap Equity Factor ETF ISCF | 0.10% | 674.5K | 0.24% |
| 9 | Avantis International Small Cap Value ETF AVDV | 0.09% | 17.93M | 0.36% |
| 10 | WisdomTree International High Dividend Fund DTH | 0.05% | 341.2K | 0.58% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
130.7K
Shares Outstanding
1.97B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wing Leung FCPA | Vice Chairman, Chief Financial Officer & Company Secretary | 5M | male |
| Hoi Shan Tsoi | Executive Chairman | 5M | male |
| Siu Chit Choy | Global Director of Intermediate & Bulk Medicine and Executive Director | 3M | female |
| Xian Hong Zou | Vice President & Executive Director | 3M | female |
| Yu Ping Fang | Vice President & Executive Director | 3M | male |
| Su Yan Zhu | Vice President & Executive Director | 3M | female |
| Wen Yu Zhang | General Manager of United Laboratories (Inner Mongolia) Limited | — | male |
| Karen Yang | Investor Relationship Director | — | female |
| Chun Lai Cao | General Manager of United Bio-Technology (Hengqin) Co., Ltd | — | male |
| Yu Bo Han | General Manager of Zhuhai United Laboratories Co., Ltd | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3933.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
